CE inhibition by the ACAT1 inhibitor avasimibe suppresses tumor growth and restores imatinib sensitivity by downregulating MAPK signaling in imatinib-resistant myeloid leukemia [92]. This evidence concerns the gene ACAT1 and neoplasm.